CStone Pharmaceuticals (CStone Pharma) filed a Next Day Disclosure Return reporting the repurchase of 0.50 million ordinary shares on 24 June 2026 via on-exchange transactions. The shares were bought at prices between HKD 4.75 and HKD 4.84, for a total consideration of HKD 2.40 million, implying a volume-weighted average price of HKD 4.80 per share.

The latest transaction lifts the running total of shares repurchased for cancellation but not yet cancelled to 3.84 million, representing approximately 0.24 % of the 1.60 billion shares in issue as of 24 June 2026. The issued share capital therefore remains unchanged at 1.60 billion shares until cancellation is completed.

The repurchase forms part of the mandate approved on 23 June 2026, which authorises the company to buy back up to 159.74 million shares. To date, 0.31 % of the authorised amount has been utilised. In line with Hong Kong Listing Rules, CStone Pharma is subject to a moratorium on issuing new shares until 24 July 2026 following the latest buyback.